Literature DB >> 20809995

Bupropion in the treatment of depression in Parkinson's disease.

Maria Załuska1, Agnieszka Dyduch.   

Abstract

A 78-year-old female with a nine-year history of depression was hospitalized due to worsening depression and symptoms associated with Parkinson's disease (PD). Her motor abilities improved on levodopa and the depression improved after a trial of bupropion, following unsuccessful treatment with other antidepressants. We found four reports on successful treatment of depression in PD with bupropion. However, no controlled double-blind studies have been conducted so clinicians should be cautious when administering bupropion in depression in PD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20809995     DOI: 10.1017/S1041610210001687

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  11 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 2.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

Review 3.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

Review 4.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

5.  Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.

Authors:  Miguel M Carvalho; Filipa L Campos; Bárbara Coimbra; José M Pêgo; Carla Rodrigues; Rui Lima; Ana J Rodrigues; Nuno Sousa; António J Salgado
Journal:  Mol Neurodegener       Date:  2013-04-26       Impact factor: 14.195

6.  Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.

Authors:  Joana Meireles; João Massano
Journal:  Front Neurol       Date:  2012-05-25       Impact factor: 4.003

Review 7.  Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review.

Authors:  Matteo Vismara; Beatrice Benatti; Gregorio Nicolini; Ilaria Cova; Edoardo Monfrini; Alessio Di Fonzo; Vincenza Fetoni; Caterina A Viganò; Alberto Priori; Bernardo Dell'Osso
Journal:  BMC Neurol       Date:  2022-05-05       Impact factor: 2.903

Review 8.  Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities.

Authors:  George R Uhl
Journal:  Ann Clin Transl Neurol       Date:  2019-01-08       Impact factor: 4.511

Review 9.  Consensus statements on the clinical understanding and use of bupropion in Hong Kong.

Authors:  Wing-King Lee; Kwok-Leung Au Yeung; Ho-Bun Lam; Chi-Keung Wong; Ting-Chi Wong; Chi-Kin Fu; Shiu-Kow Sham; Ming-Kai Au; Tat-Chung Lam; Daniel Ki-Yan Mak
Journal:  CNS Neurosci Ther       Date:  2021-03       Impact factor: 5.243

10.  Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease.

Authors:  Christopher C Yang; Mengnan Zhao
Journal:  J Med Internet Res       Date:  2018-10-11       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.